APA (7th ed.) Citation
(2026). Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins. PLOS ONE.
Chicago Style (17th ed.) Citation
"Correction: Evaluating the Pentapharmacological Potency of Otamixaban Against Lung Cancer CDK2, Transferase, Oxidoreductase and Signalling Proteins." PLOS ONE 2026.
MLA (9th ed.) Citation
"Correction: Evaluating the Pentapharmacological Potency of Otamixaban Against Lung Cancer CDK2, Transferase, Oxidoreductase and Signalling Proteins." PLOS ONE, 2026.
Warning: These citations may not always be 100% accurate.